Monoclonal antibody recommended by NICE for active psoriatic arthritis

Ustekinumab (Stelara) has been accepted by NICE for treating adults with active psoriatic arthritis.

 Ustekinumab is recommended as a treatment option when treatment with DMARDS has not worked well enough. | SCIENCE PHOTO LIBRARY
Ustekinumab is recommended as a treatment option when treatment with DMARDS has not worked well enough. | SCIENCE PHOTO LIBRARY

In its latest technology appraisal of ustekinumab, NICE has overridden its previous decision to reject the monoclonal antibody for the treatment of psoriatic arthritis.

Ustekinumab is now recommended, either alone or in combination with methotrexate, in adults when:

  • treatment with tumour necrosis factor (TNF) inhibitors is contraindicated but would otherwise be considered or
  • the person has already been treated with a TNF inhibitor

Further information
NICE technology appraisal TA340

If there is inadequate improvement in the patient's condition according to the Psoriatic Arthritis Response Criteria (PsARC) at 24 weeks, ustekinumab treatment should be stopped. Patients who experience a Psoriasis Area and Severity Index (PASI) 75 response, but whose PsARC response does not justify continuing treatment, should be assessed by a dermatologist to determine whether ongoing treatment is appropriate on the basis of skin response.

Acceptance by NICE is conditional on the manufacturer providing the 90mg dose of ustekinumab for people who weigh more than 100kg at the same cost as the 45mg dose, as agreed in the patient access scheme.

Ustekinumab is administered by subcutaneous injection. It binds to and inhibits interleukins 12 and 23.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more